All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
To help navigate the exciting content being presented at the EHA 2022 Congress, the MPN Hub Steering Committee members have provided their recommendations of the top abstracts to look for in the following categories: clinical trial updates, real-world data, MPN and COVID-19, and translational data in MPN.
BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis — JAK inhibitor-naïve or with suboptimal response to ruxolitinib — preliminary data from the manifest study
To download this document, click below.Download here
Subscribe to get the best content related to MPN delivered to your inbox